Also, the magnitude of change in ALT is small relative to that associated with variants in PNPLA3, HSD17B13, mitochondrial amidoxime reducing component 1 (MTARC1), and TM6SF2. This might account for the absence of this variant (or others near MBOAT7) from GWAS for NAFLD in the general population.1 This evidence concerns the gene MTARC1 and metabolic dysfunction-associated steatotic liver disease.